HUT70484A - Process for preparing pharmaceutical compositions for treating incontinence of feces and urine containing modafinil - Google Patents
Process for preparing pharmaceutical compositions for treating incontinence of feces and urine containing modafinil Download PDFInfo
- Publication number
- HUT70484A HUT70484A HU9303004A HU9303004A HUT70484A HU T70484 A HUT70484 A HU T70484A HU 9303004 A HU9303004 A HU 9303004A HU 9303004 A HU9303004 A HU 9303004A HU T70484 A HUT70484 A HU T70484A
- Authority
- HU
- Hungary
- Prior art keywords
- modafinil
- urinary
- sphincter
- isomers
- feces
- Prior art date
Links
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 229960001165 modafinil Drugs 0.000 title claims abstract description 33
- 206010046543 Urinary incontinence Diseases 0.000 title claims abstract description 11
- 208000034347 Faecal incontinence Diseases 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 210000002700 urine Anatomy 0.000 title description 2
- 210000005070 sphincter Anatomy 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 230000002485 urinary effect Effects 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 12
- 210000005071 external anal sphincter Anatomy 0.000 description 9
- 210000003932 urinary bladder Anatomy 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000000626 ureter Anatomy 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000003202 urodynamic effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229940127250 psychostimulant medication Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002620 ureteric effect Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9212700A FR2697162B1 (fr) | 1992-10-23 | 1992-10-23 | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HU9303004D0 HU9303004D0 (en) | 1994-01-28 |
| HUT70484A true HUT70484A (en) | 1995-10-30 |
Family
ID=9434826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9303004A HUT70484A (en) | 1992-10-23 | 1993-10-22 | Process for preparing pharmaceutical compositions for treating incontinence of feces and urine containing modafinil |
Country Status (9)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| DK0946155T4 (da) † | 1996-12-23 | 2009-05-11 | Sla Pharma Ag | Farmaceutisk sammensætning til behandling af fækal inkontinens |
| CA2280309C (en) * | 1999-08-13 | 2007-05-08 | William Norton Milgram | Use of adrafinil to treat behavioral problems in aged canines |
| US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| US6492396B2 (en) * | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| CN100584322C (zh) * | 2000-10-11 | 2010-01-27 | 赛福伦公司 | 包含莫达非尼化合物的组合物 |
| US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
| IL158959A (en) * | 2001-05-25 | 2010-06-30 | Cephalon Inc | Solid pharmaceutical formulations comprising modafinil |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| IL153098A0 (en) * | 2002-11-26 | 2003-06-24 | Chemagis Ltd | Pharmaceutical compositions containing modafinil |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| AR045423A1 (es) * | 2003-05-13 | 2005-10-26 | Cephalon Inc | Combinaciones de analiticos y antidepresivos |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| US7297817B2 (en) * | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| US7423176B2 (en) * | 2004-04-13 | 2008-09-09 | Cephalon, Inc. | Bicyclic aromatic sulfinyl derivatives |
| US7449481B2 (en) * | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
| US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
| US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| EP1586560A1 (en) * | 2004-04-13 | 2005-10-19 | Cephalon, Inc. | Thio-substituted arylmethanesulfinyl derivatives |
| US20060024370A1 (en) | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| US7553273B2 (en) | 2006-05-01 | 2009-06-30 | Duodyn Technology, Llc | Apparatus and method for managing incontinence |
| BRPI0714173A2 (pt) * | 2006-07-12 | 2012-12-25 | Elan Pharma Int Ltd | composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem |
| US20080181966A1 (en) * | 2006-10-18 | 2008-07-31 | Cephalon, Inc. | Modafinil pharmaceutical compositions |
| US20090325999A1 (en) * | 2008-06-27 | 2009-12-31 | Jie Du | Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions |
| KR101345860B1 (ko) | 2011-10-25 | 2013-12-30 | 이화여자대학교 산학협력단 | 모다피닐 또는 이의 유도체를 포함하는 혈관질환 치료용 조성물 |
| WO2013062316A2 (ko) * | 2011-10-25 | 2013-05-02 | 이화여자대학교 산학협력단 | 모다피닐 또는 이의 유도체를 포함하는 혈관질환 또는 ＫＣａ3.1 채널 매개 질환 치료용 조성물 |
| EP3854409A1 (en) | 2013-08-30 | 2021-07-28 | Green Cross Wellbeing Corporation | Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent |
| US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| FR2684875B1 (fr) * | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
-
1992
- 1992-10-23 FR FR9212700A patent/FR2697162B1/fr not_active Expired - Fee Related
-
1993
- 1993-10-18 TW TW082108634A patent/TW278041B/zh active
- 1993-10-18 US US08/137,417 patent/US5401776A/en not_active Expired - Fee Related
- 1993-10-18 CA CA002108593A patent/CA2108593A1/en not_active Abandoned
- 1993-10-19 AU AU49085/93A patent/AU667962B2/en not_active Ceased
- 1993-10-20 EP EP93402581A patent/EP0594507A1/fr not_active Withdrawn
- 1993-10-21 KR KR1019930021926A patent/KR940008686A/ko not_active Withdrawn
- 1993-10-22 JP JP5264854A patent/JPH06192077A/ja active Pending
- 1993-10-22 HU HU9303004A patent/HUT70484A/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2697162A1 (fr) | 1994-04-29 |
| JPH06192077A (ja) | 1994-07-12 |
| CA2108593A1 (en) | 1994-04-24 |
| AU667962B2 (en) | 1996-04-18 |
| FR2697162B1 (fr) | 1995-01-13 |
| KR940008686A (ko) | 1994-05-16 |
| TW278041B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1996-06-11 |
| US5401776A (en) | 1995-03-28 |
| AU4908593A (en) | 1994-05-05 |
| HU9303004D0 (en) | 1994-01-28 |
| EP0594507A1 (fr) | 1994-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUT70484A (en) | Process for preparing pharmaceutical compositions for treating incontinence of feces and urine containing modafinil | |
| US7676269B2 (en) | Treatment of female fertility conditions through modulation of the autonomic nervous system | |
| EP3840825A1 (en) | Transcutaneous electrical and/or magnetic spinal stimulation for bladder or bowel control in subjects without cns injury | |
| US11925802B2 (en) | Peripheral neuromodulation to treat bladder and bowel dysfunction | |
| RU2095060C1 (ru) | Композиция, обладающая аналгетической или противовоспалительной активностью, способ аналгезии или лечения аллергических заболеваний | |
| Hemmy et al. | The effect of cerebellar stimulation on focal seizure activity and spasticity in monkeys | |
| Kaplan et al. | Intravesical transurethral electrotherapy for the neurogenic bladder | |
| Binnie et al. | The action of cisapride on the chronic constipation of paraplegia | |
| Ishigooka et al. | Electrical pelvic floor stimulation: a possible alternative treatment for reflex urinary incontinence in patients with spinal cord injury | |
| Talalla et al. | The effect of intrathecal baclofen on the lower urinary tract in paraplegia | |
| JP2004524270A (ja) | 長時間作用する麻酔薬および鎮痛薬としての、三環式抗うつ薬およびのそれらのアナログ | |
| Beyak et al. | Superior laryngeal nerve stimulation in the cat: effect on oropharyngeal swallowing, oesophageal motility and lower oesophageal sphincter activity | |
| Koldewijn et al. | Use of sacral reflex latency measurements in the evaluation of neural function of spinal cord injury patients: a comparison of neuro-urophysiological testing and urodynamic investigations | |
| Talus et al. | Spinal cord stimulation in peripheral vascular disease | |
| EP3909570A1 (de) | Oxybutynin für die intravesikale anwendung | |
| RU2605290C2 (ru) | Оксиметазолин для лечения аноректальных нарушений | |
| He et al. | Low-Intensity Ultrasound Tibial Nerve Stimulation Suppresses Bladder Activity in Rats | |
| Gernon et al. | Some Recent Developments in the Treatment of Neurogenic Dysfunction of the Bladder: Based on Cystometry | |
| Petersen | Management of urinary incontinence in children with myelomeningocele | |
| Mohamed et al. | Efficacy of biofeedback and precautenous tibial nerve stimulation on functional faecal incontinence in children | |
| JPH01125330A (ja) | 尿道内圧増強剤 | |
| Findlay et al. | Posterior tibial nerve stimulation for faecal incontinence | |
| Elshora et al. | Posterior tibial nerve stimulation vs trospium chloride in treatment of overactive bladder in elderly women | |
| DE202020103897U1 (de) | Oxybutynin für die intravesikale Anwendung | |
| Whitehead | S1845 National Health and Nutrition Examination Survey (NHANES) of Fecal Incontinence: Prevalence By Sex, Age, Race, Marital Status, Education, and Income |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DFC4 | Cancellation of temporary protection due to refusal |